Compare TGE & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | THAR |
|---|---|---|
| Founded | 2023 | 2017 |
| Country | France | United States |
| Employees | N/A | 3 |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 90.8M |
| IPO Year | N/A | 2022 |
| Metric | TGE | THAR |
|---|---|---|
| Price | $1.09 | $2.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 160.2K | ★ 369.0K |
| Earning Date | 10-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $130,212,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.32 | ★ N/A |
| Revenue Growth | ★ 316.50 | N/A |
| 52 Week Low | $0.78 | $0.95 |
| 52 Week High | $37.02 | $9.08 |
| Indicator | TGE | THAR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.51 |
| Support Level | N/A | $2.20 |
| Resistance Level | N/A | $2.62 |
| Average True Range (ATR) | 0.00 | 0.19 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 0.00 | 85.51 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.